Moderna, Inc. (NASDAQ:MRNA) has delivered a major boost to its turnaround story. Its personalized mRNA cancer vaccine, Intismeran, met the main goal of reducing melanoma recurrence and also showed a benefit in preventing the cancer from spreading when used with Merck’s Keytruda. The result is especially important because it is the first positive late-stage trial for an mRNA cancer vaccine and the first study to show that an individualized treatment can improve outcomes beyond Keytruda alone.
The news gives Moderna a credible path to reduce its dependence on COVID products. If regulators approve the treatment, both companies could potentially launch it as early as next year, giving Moderna a new commercial opportunity in oncology.
Bull Case
The biggest positive for Moderna, Inc. (NASDAQ:MRNA) is that Intismeran could become the product that changes the company’s growth story. Moderna has spent years trying to build a business beyond COVID vaccines, and a successful cancer treatment would give investors a much stronger reason to believe in its mRNA platform.
The clinical result is also important beyond melanoma. The vaccine is personalized around mutations found in an individual patient’s tumor, which could make the technology useful across several types of cancer. Moderna and Merck are already studying similar approaches in lung, breast and pancreatic cancers. Strong results in melanoma could therefore increase confidence in those programs as well.
There is also a meaningful commercial opportunity. Barclays analysts have estimated that Intismeran could generate around $3 billion in annual melanoma sales by 2035. J.P. Morgan has gone further in emphasizing the importance of the treatment to Moderna’s return to profitability.
The partnership with Merck strengthens the opportunity. Keytruda already has a large presence in cancer treatment, so combining it with a personalized vaccine gives Moderna access to an established treatment ecosystem rather than requiring the company to build an oncology franchise from scratch.
The result could also restore confidence in Moderna, Inc. (NASDAQ:MRNA)’s broader mRNA technology. The company has faced questions about whether it can turn its COVID-era success into a sustainable pipeline. A successful cancer vaccine would provide the clearest evidence yet that its technology has applications well beyond infectious diseases.
Bear Case
The biggest concern is that the market may have priced in a lot of good news very quickly. Moderna, Inc. (NASDAQ:MRNA) shares surged as much as 160% and added almost $40 billion to its market value. That kind of move creates a high bar for future results. Even if Intismeran is eventually approved, investors could become disappointed if sales ramp up more slowly than expected.
The current results are also interim findings, and the companies have not yet released the detailed data. Investors still need to see the actual magnitude of the benefit, statistical details, and longer-term outcomes. A positive headline does not necessarily tell the full story.
Commercialization could be another challenge. Unlike a conventional vaccine that can be produced in large batches, Intismeran is personalized for each patient based on the mutations in their tumor. Manufacturing thousands of individualized treatments efficiently and quickly could prove complicated and expensive.
Regulatory approval is not guaranteed either. Although Moderna and Merck are already talking with regulators and the treatment has breakthrough therapy designation, additional data and regulatory scrutiny will still be required. There is also a broader pipeline risk. Moderna’s long-term valuation cannot depend entirely on one melanoma treatment. The company still needs its other oncology programs and non-COVID products to deliver meaningful results. Success in melanoma does not automatically mean the same approach will work in lung, breast, or pancreatic cancer.
Finally, pricing and reimbursement remain unanswered. Moderna, Inc. (NASDAQ:MRNA) has not yet decided how much Intismeran will cost. Since the treatment is personalized and could require complex manufacturing, pricing will need to balance the value of the therapy with the cost of producing it. That could affect how quickly it reaches patients and how much revenue it ultimately generates.
Conclusion
The Intismeran results are a genuine turning point for Moderna, Inc. (NASDAQ:MRNA). This is not simply another positive clinical update; it provides early evidence that the company’s mRNA technology can work in a completely different area from COVID vaccines. If the treatment receives approval and can be produced at scale, it could become an important source of revenue and help put Moderna back on a path toward profitability.
Still, investors should separate the clinical breakthrough from the investment case. The share price has already reacted dramatically, while important details around the trial data, regulatory approval, manufacturing, and pricing are still unresolved.
Overall, the news is strongly bullish for Moderna’s long-term story, but the sharp stock rally means expectations are now much higher. The next major test will be whether Moderna can turn an impressive clinical result into a commercially successful product.
While we acknowledge the risk and potential of MRNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRNA and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: Marvell Technology (MRVL) Expands Google AI Partnership: What Investors Need to Know and Target Corporation (TGT) vs. Walmart (WMT): A Closer Look at Two Dividend Giants
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center